Literature DB >> 28199724

Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.

Inge A M van den Oever1, Maaike Heslinga1, Ed N Griep2, Hanneke R M Griep-Wentink2, Rob Schotsman3, Walter Cambach4, Ben A C Dijkmans5, Yvo M Smulders5, Willem F Lems1,6, Maarten Boers1,6, Alexandre E Voskuyl7, Mike J L Peters5, Dirkjan van Schaardenburg1,7, Micheal T Nurmohamed1,6.   

Abstract

Objective: To assess the 10-year cardiovascular (CV) risk score and to identify treatment and undertreatment of CV risk factors in patients with established RA.
Methods: Demographics, CV risk factors and prevalence of cardiovascular disease (CVD) were assessed by questionnaire. To calculate the 10-year CV risk score according to the Dutch CV risk management guideline, systolic blood pressure was measured and cholesterol levels were determined from fasting blood samples. Patients were categorized into four groups: indication for treatment but not treated; inadequately treated, so not meeting goals (systolic blood pressure ⩽140 mmHg and/or low-density lipoprotein ⩽2.5 mmol/l); adequately treated; or no treatment necessary.
Results: A total of 720 consecutive RA patients were included, 375 from Reade and 345 from the Antonius Hospital. The mean age of patients was 59 years (s.d. 12) and 73% were female. Seventeen per cent of the patients had a low 10-year CV risk (<10%), 21% had an intermediate risk (10-19%), 53% a high risk (⩾20%) and 9% had CVD. In total, 69% had an indication for preventive treatment (cholesterol-lowering or antihypertensive drugs). Of those, 42% received inadequate treatment and 40% received no treatment at all.
Conclusion: Optimal CV risk management remains a major challenge and better awareness and management are urgently needed to reduce the high risk of CVD in the RA population.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  cardiovascular disease; cardiovascular risk management; rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 28199724     DOI: 10.1093/rheumatology/kew497

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  9 in total

1.  Metabolic abnormalities in rheumatoid arthritis patients with comorbid diabetes mellitus.

Authors:  Xing Zhen Liu; Ying Gao; Jie Fan; Xia Xu; Ju Zhang; Jie Gao; Wei Wan; Dong Bao Zhao
Journal:  Clin Rheumatol       Date:  2017-09-24       Impact factor: 2.980

Review 2.  Cardiovascular risk in patients with rheumatoid arthritis.

Authors:  Kim Lauper; Cem Gabay
Journal:  Semin Immunopathol       Date:  2017-04-28       Impact factor: 9.623

3.  Stiffening of aorta is more preferentially associated with rheumatoid arthritis than peripheral arteries.

Authors:  Yong Yang; Zhen Wang; Zihao Fu; Runrun Yang; Jia Wang; Lijun Yuan; Feng Gao; Yunyou Duan
Journal:  Rheumatol Int       Date:  2019-08-02       Impact factor: 2.631

4.  Erectile Dysfunction and Cardiovascular Risk in Men With Rheumatoid Arthritis: A Population-based Cohort Study.

Authors:  Katelynn M Wilton; Sara J Achenbach; John M Davis; Elena Myasoedova; Eric L Matteson; Cynthia S Crowson
Journal:  J Rheumatol       Date:  2021-01-15       Impact factor: 5.346

5.  Cardiovascular risk screening of patients with serious mental illness or use of antipsychotics in family practice.

Authors:  Kirsti M Jakobs; Anne Posthuma; Wim J C de Grauw; Bianca W M Schalk; Reinier P Akkermans; Peter Lucassen; Tjard Schermer; Willem J J Assendelft; Marion J C Biermans
Journal:  BMC Fam Pract       Date:  2020-07-29       Impact factor: 2.497

6.  Cardiovascular risk management in rheumatoid and psoriatic arthritis: online survey results from a national cohort study.

Authors:  Premarani Sinnathurai; Alexandra Capon; Rachelle Buchbinder; Vibhasha Chand; Lyndall Henderson; Marissa Lassere; Lyn March
Journal:  BMC Rheumatol       Date:  2018-09-06

Review 7.  Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future.

Authors:  Lun Wang; Yang Zhang; Shu-Yang Zhang
Journal:  Chin Med J (Engl)       Date:  2019-12-20       Impact factor: 2.628

8.  Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus.

Authors:  Eleana Bolla; Nikolas Tentolouris; Petros P Sfikakis; Maria G Tektonidou
Journal:  Lupus Sci Med       Date:  2021-12

9.  Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study.

Authors:  Dorien M C F Sluijsmans; Daphne C Rohrich; Calin D Popa; Bart J F van den Bemt
Journal:  J Clin Med       Date:  2021-05-05       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.